TENX - Tenax Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.2000
-0.0400 (-3.23%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.2400
Open1.2126
Bid1.2000 x 1200
Ask1.2700 x 800
Day's Range1.1920 - 1.2300
52 Week Range1.0300 - 2.7900
Volume35,556
Avg. Volume30,810
Market Cap8.1M
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-3.0370
Earnings DateNov 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.22
  • TENX: Tenax’ HELP Update
    Zacks Small Cap Research

    TENX: Tenax’ HELP Update

    By John Vandermosten, CFA NASDAQ:TENX Tenax Therapeutics (NASDAQ:TENX) announced on October 31st that it had enrolled 15 of 36 patients in its Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF (HELP) trial. The company also announced the average reduction in average pulmonary capillary wedge pressure (PCWP) for the successfully screened patients of 8 mmHg. As a reminder, the

  • Business Wire

    Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan. Tenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

  • We're A Little Worried About Tenax Therapeutics's (NASDAQ:TENX) Cash Burn Rate
    Simply Wall St.

    We're A Little Worried About Tenax Therapeutics's (NASDAQ:TENX) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • TENX: Focused on the Enrollment Phase
    Zacks Small Cap Research

    TENX: Focused on the Enrollment Phase

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2019 Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) began activating sites for its H emodynamic E valuation of L evosimendan in P atients with PH-HFpEF (HELP) trial in late 2018. After a thorough screening process, the first patient was

  • What Kind Of Investor Owns Most Of Tenax Therapeutics, Inc. (NASDAQ:TENX)?
    Simply Wall St.

    What Kind Of Investor Owns Most Of Tenax Therapeutics, Inc. (NASDAQ:TENX)?

    The big shareholder groups in Tenax Therapeutics, Inc. (NASDAQ:TENX) have power over the company. Institutions will...

  • Zacks Small Cap Research

    TENX: Screening & Enrollment Continue

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT First Quarter 2019 Financial and Operational Review Following the December 2018 activation of trial sites, Tenax Therapeutics, Inc. ...

  • Zacks Small Cap Research

    TENX: HELP Trial Enrollment Underway

    By John Vandermosten, CFA NASDAQ:TENX READ THE LATEST TENX RESEARCH REPORT 2018 Financial and Operational Review During 2018 Tenax Therapeutics, Inc. (NASDAQ:TENX) re-aligned the company towards the development ...

  • Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%
    Simply Wall St.

    Introducing Tenax Therapeutics (NASDAQ:TENX), The Stock That Collapsed 98%

    Tenax Therapeutics, Inc. (NASDAQ:TENX) shareholders will doubtless be very grateful to see the share price up 64% in the last quarter. But will that heal all the wounds inflicted overRead More...

  • Business Wire

    Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the first patient has been randomized for the Company’s Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study, also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF), is designed to enroll a total of 36 PH-HFpEF patients at up to approximately 10-12 major research institutions across the US. Anthony DiTonno, CEO of Tenax Therapeutics, Inc., stated, “Enrolling our first patient is an important milestone for the HELP trial.

  • ACCESSWIRE

    Four Biotech Stocks Setting The Standard On Thursday (2/21/19)

    CORAL GABLES, FL/ ACCESSWIRE / February 21, 2019 / The future of the biotech stock market is dependent on whether medical experts have the ability to continue pioneering advancements in medicine and other innovative solutions to curing diseases. As companies in the biotech sector continue to develop medicines that address the significant needs of patients, these innovations could catalyze significant investor attention. Premier Health Group (PHGRF) (PHGI), AVEO Pharmaceuticals Inc (AVEO), Adial Pharmaceuticals Inc (ADIL), and Tenax Therapeutics Inc (TENX) represent four biotech stocks that are testing their limits on Thursday. Premier Health Group (PHGRF) (PHGI) is a Canadian publicly traded company strategically poised to take advantage of potential opportunities in the global healthcare industry.

  • Business Wire

    Tenax Therapeutics to Present at 2019 BIO CEO & Investor Conference

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with high unmet medical need, today announced that management is scheduled to present and conduct one-on-one meetings at the 2019 BIO CEO & Investor Conference to be held in New York, NY on February 11th and 12th. Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with high unmet medical need. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension.

  • Business Wire

    Tenax Therapeutics to Present at Biotech Showcase Investor Conference

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying and developing drugs that address diseases with high unmet medical need, today announced that the Company will participate in Biotech Showcase Investor Conference in San Francisco, which takes place January 7-9, 2019. Biotech Showcase™ is an investor conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals.